Funen biotech company makes international breakthrough

Biotech company Alphalyse A/S took a major gamble on their method for detecting and measuring microscopic amounts of impurities in pharmaceuticals – a gamble that has paid off.

With official approval and recognition from the U.S. Pharmacopeia – an independent organization that sets quality standards for medicines in the U.S. – Alphalyse has developed what is likely the world’s most advanced method for assessing when a pharmaceutical product is safe to use.

Their technique is now being described as a best-practice approach to pharmaceutical analysis.

The U.S. Food and Drug Administration (FDA) always refers to best practices when biotech companies submit new pharmaceuticals – and that’s exactly the type of data Alphalyse provides.

According to Professor Peter Højrup from the University of Southern Denmark (SDU), Alphalyse’s method is significantly more powerful than previous solutions—a strength that has already attracted major pharmaceutical companies as clients.

This has doubled the company’s revenue over the past ten years, and Alphalyse now employs 35 people in Odense.

The company is still owned by its founders, Thomas Kofoed and Ejvind Mørtz, with Torben Frigaard Rasmussen serving as Chairman of the Board and strategic advisor.
Read the full article about Alphalyse’s breakthrough here.